Comparing SG&A Expenses: Biogen Inc. vs Madrigal Pharmaceuticals, Inc. Trends and Insights

SG&A Expenses: A Tale of Two Biotech Giants

In the competitive world of biotechnology, understanding the financial strategies of industry leaders is crucial. Biogen Inc. and Madrigal Pharmaceuticals, Inc. offer a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses. Over the past decade, Biogen's SG&A expenses have shown a steady increase, peaking in 2021 with a 38% rise from 2014. This reflects their aggressive market expansion and investment in administrative capabilities. In contrast, Madrigal Pharmaceuticals, Inc. has seen a dramatic surge in SG&A expenses, skyrocketing by over 580% from 2014 to 2023. This sharp increase highlights Madrigal's rapid growth phase and strategic investments in marketing and sales. The data underscores the differing strategies of these two companies, with Biogen focusing on steady growth and Madrigal on rapid expansion. Understanding these trends provides valuable insights into the financial health and strategic priorities of these biotech giants.